Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal to Expand Rare Disease Portfolio
French pharma giant Sanofi is set to acquire U.S.-based biotech firm Blueprint Medicines in a landmark deal valued at up to $9.5 billion, targeting leadership in rare disease treatments.
The move highlights Sanofi’s bold pivot toward high-growth immunology and precision medicine. At $129 per share plus milestone-linked incentives, the deal grants Sanofi access to breakthrough therapies like Ayvakit and BLU-808.
French pharmaceutical giant Sanofi has announced a definitive agreement to acquire U.S.-based biotech firm Blueprint Medicines for up to $9.5 billion, in a move set to significantly bolster its position in immunology and rare disease treatment.
Deal breakdown
Under the terms of the deal, Sanofi will purchase Blueprint Medicines at $129 per share in cash, valuing the company at approximately $9.1 billion. In addition, Blueprint shareholders will receive a non-tradeable contingent value right (CVR) worth up to $6 per share, tied to specific regulatory and development milestones related to BLU-808, a promising investigational KIT inhibitor. The total value of the deal could thus rise to $9.5 billion.
Strategic value
Sanofi’s acquisition is aimed at strengthening its pipeline in rare immunological conditions. At the heart of the deal is Ayvakit (avapritinib), Blueprint’s flagship drug for systemic mastocytosis (SM), a rare and debilitating immune cell disorder. Already approved in both the U.S. and EU, Ayvakit earned nearly $150 million in Q1 2025 alone and is projected to hit $2 billion in annual revenue by 2030.
In addition to Ayvakit, Sanofi will gain access to elenestinib, a next-generation SM therapy, and BLU-808, which targets a broader spectrum of immunological conditions, further solidifying Sanofi’s ambitions to lead in rare disease innovation.
Market response
The market responded with enthusiasm. Shares of Blueprint Medicines surged 26% in intraday trading following the announcement, reflecting strong investor confidence in the deal’s long-term value and Blueprint’s commercial prospects.
A strategic fit
This acquisition is the latest in a series of bold moves by Sanofi to deepen its presence in high-growth biotech segments. It follows recent exits from slower-performing markets and underscores CEO Paul Hudson’s strategy to pivot Sanofi toward specialty care and precision medicine.
“The acquisition of Blueprint reflects our unwavering commitment to immunology and rare diseases,” said Hudson. “By integrating Blueprint’s portfolio, we not only enhance our treatment offerings but also push the frontiers of scientific innovation in underserved patient populations.”
With the deal expected to close later in 2025 pending regulatory approvals, Sanofi is signaling to the market that it is betting big on rare diseases, not just for future profits, but for leadership in next-gen therapeutics.
